Alps Advisors Inc. Increases Holdings in Gilead Sciences, Inc. $GILD

Alps Advisors Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 171.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,913 shares of the biopharmaceutical company’s stock after buying an additional 34,083 shares during the quarter. Alps Advisors Inc.’s holdings in Gilead Sciences were worth $5,984,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. Norges Bank purchased a new stake in Gilead Sciences during the second quarter valued at about $2,150,268,000. Ameriprise Financial Inc. boosted its holdings in Gilead Sciences by 397.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock valued at $748,147,000 after acquiring an additional 5,392,191 shares during the period. Invesco Ltd. boosted its holdings in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. grew its position in Gilead Sciences by 164.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after acquiring an additional 2,169,266 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer owned 613,912 shares of the company’s stock, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 373,037 shares of company stock valued at $50,731,512 over the last ninety days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $152.50 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $153.13. The stock’s 50 day simple moving average is $127.38 and its two-hundred day simple moving average is $121.04. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock has a market cap of $189.20 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 0.80 and a beta of 0.36.

Analysts Set New Price Targets

A number of analysts have recently weighed in on GILD shares. Wolfe Research increased their price objective on Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research note on Wednesday, January 28th. Leerink Partners upped their price target on shares of Gilead Sciences from $114.00 to $146.00 and gave the company an “outperform” rating in a report on Friday, January 30th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Truist Financial upped their price objective on shares of Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, Daiwa Securities Group increased their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.